Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Description

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

Conditions

Covid19

Talk to us

Study Overview

On this page

Study Details

Study overview

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Condition
Covid19
Intervention / Treatment

-

Contacts and Locations

Mobile

University of South Alabama, Mobile, Alabama, United States, 36617

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or Female age 18 or older
  • 2. On high flow oxygen =/\> 6 liters nasal cannula (or)
  • 3. On mechanical ventilation
  • 4. Clinical diagnosis of COVID-19 \& positive PCR test (or)
  • 5. Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan
  • 1. Known allergy to Pulmozyme
  • 2. Less than 18 years of age
  • 3. Grave condition with anticipated death within 48 hours; at the discretion of treating physician.
  • 4. Enrollment in another clinical trial receiving investigatory drugs

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jon Simmons,

Study Record Dates

2022-02-28